IMMUNIC, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
IMUX$8.04+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
| Page | ||
| Report of Baker Tilly US, LLP, Independent Registered Public Accounting Firm | F-2 | |
|---|---|---|
| Consolidated Balance Sheets | F-3 | |
| Consolidated Statements of Operations | F-4 | |
| Consolidated Statements of Comprehensive Loss | F-5 | |
| Consolidated Statements of Stockholders’ Equity (Deficit) | F-6 | |
| Consolidated Statements of Cash Flows | F-7 | |
| Notes to Consolidated Financial Statements | F-8 | |
| 2. Financial Statement Schedules. None. | ||
| 3. Exhibits. The following exhibits are filed herewith or are incorporated by reference to exhibits previously | ||
| filed with the U.S. Securities and Exchange Commission. | ||
EXHIBITS
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber · Exhibit Title · Form · Exhibit · Filing Date | |||||
| 1.1 | Underwriting Agreement | 8-K | 1.1 | May 30, 2025 | |
| 3.1 | Amended and Restated Certificate of Incorporation. | 8-K | 3.1 | July 17, 2019 | |
| 3.2 | Third Amended and Restated Bylaws. | 8-K | 3.1 | July 17, 2019 | |
| 3.3 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Immunic, Inc. | 8-K | 3.1 | March 8, 2024 | |
| 4.1 | 2019 Omnibus Equity Incentive Plan, as amended, | S-8 | 4.2 | August 21, 2023 | |
| 4.2+ | Amended and Restated 2021 Employee Stock Purchase Plan. | S-8 | 10.3 | July 28, 2021 | |
| 4.3* | Description of Registrant’s Securities | ||||
| 4.4 | Form of Pre-Funded Warrant | 8-K | 4.1 | January 4, 2024 | |
| 4.5 | Form of Placement Agent Warrant | 8-K | 4.1 | April 9, 2025 | |
| 4.6 | Form of Pre-funded Warrant | 8-K | 4.1 | May 30, 2025 | |
| 4.7 | Form of Series A Warrant | 8-K | 4.2 | May 30, 2025 | |
| 4.8 | Form of Series B Warrant | 8-K | 4.3 | May 30, 2025 | |
| 4.9 | Form of Pre-funded Warrant | 8-K | 4.1 | February 13, 2026 | |
| 4.10 | Form of Common Warrant | 8-K | 4.2 | February 13, 2026 | |
| 10.1+ | Addendum No. 6, dated August 29, 2024, to Employment Agreement, dated April 17, 2020, between Immunic, Inc. and Duane Nash. | 8-K | 10.1 | September 3, 2024 | |
| 10.2+ | Employment Agreement, dated December 18, 2023, between Immunic, Inc. and Dr. Andreas Muehler. | 8-K | 10.3 | December 18, 2023 | |
| 10.3 | Fifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Daniel Vitt. | 8-K | 10.1 | December 18, 2023 | |
| 10.4 | Fifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Andreas Muehler. | 8-K | 10.2 | December 18, 2023 | |
| 10.5 | Fifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Hella Kohlhof. | 8-K | 10.4 | December 18, 2023 | |
| 10.6 | Securities Purchase Agreement, dated January 4, 2024, by and among the Company and the Investors. | 8-K | 10.1 | January 4, 2024 | |
| 10.7 | Form of Indemnification Agreement. | 8-K | 10.4 | July 17, 2019 | |
| 10.8 | Service Agreement, dated August 22, 2016, between Immunic AG and Dr. Andreas Muehler. | 10-K | 10.5 | February 23, 2023 | |
| 10.9 | Service Agreement, dated September 29, 2016, between Immunic AG and Daniel Vitt. | 10-K | 10.6 | February 23, 2023 | |
| 10.10+ | Employment Agreement between Dr. Daniel Vitt and Immunic AG. | 8-K | 10.5 | July 17, 2019 | |
| 10.11+ | Employment Agreement, dated September 4, 2019, between Immunic, Inc. and Dr. Andreas Muehler. | 8-K | 99.3 | September 5, 2019 | |
| 10.12+ | Employment Agreement dated April 17, 2020, between Immunic, Inc. and Duane Nash. | 8-K | 10.2 | April 20, 2020 | |
| 10.13+ | Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Dr. Andreas Muehler | 8-K | 10.3 | June 10, 2021 | |
| 10.14+ | Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Glenn Whaley | 8-K | 10.4 | June 10, 2021 | |
| 10.15+ | Employment Agreement, dated October 14, 2021, between Immunic, Inc. and Patrick Walsh | 8-K | 10.1 | October 14, 2021 | |
| 10.16+ | Employee Agreement, dated July 9, 2024, between Immunic, Inc. and Jason Tardio | 10-Q | 10.16 | August 8, 2024 | |
| 10.17 | Employment agreement dated December 13, 2024, between Immunic, Inc. and Dr. Daniel Vitt | 8-K | 10.1 | December 18, 2024 | |
| 10.18 | Amended and Restated 2021 Employee Stock Purchase Plan | S-8 | 4.4 | July 2, 2024 | |
| 10.19 | 2019 Omnibus Equity Incentive Plan, as amended | 8-K | 10.1 | June 4, 2025 | |
| 10.20 | Form of Placement Agency Agreement | 8-K | 10.1 | April 9, 2025 | |
| 10.21 | Form of Securities Purchase Agreement | 8-K | 10.2 | April 9, 2025 | |
| 10.22 | Employment Agreement, dated December 29, 2025, between Immunic, Inc. and Dr. Duane Nash. | Employment Agreement, dated December 29, 2025, between Immunic, Inc. and Dr. Duane Nash. | 8-K | 10.1 | January 5, 2026 |
| 10.23 | Employment Agreement, dated December 29, 2025, between Immunic, Inc. and Dr. Daniel Vitt. | Employment Agreement, dated December 29, 2025, between Immunic, Inc. and Dr. Daniel Vitt. | 8-K | 10.2 | January 5, 2026 |
| 10.24 | Addendum to Service Agreement, dated December 29, 2025, between Immunic AG and Dr. Daniel Vitt. | 8-K | 10.3 | January 5, 2026 | |
| 10.25 | Form of Securities Purchase Agreement, dated February 12, 2026 by and among Immunic, Inc. and the purchasers named therein. | 8-K | 10.1 | February 13, 2026 | |
| 10.26 | Form of Registration Rights Agreement, dated February 12, 2026 by and among Immunic, Inc. and the holders named therein. | 8-K | 10.2 | February 13, 2026 | |
| 10.27 | Form of Purchase and Sale Agreement, dated February 12, 2026 by and amongImmunic, Inc., the holders named therein, and BVF Partners, L.P. | Form of Purchase and Sale Agreement, dated February 12, 2026 by and among Immunic, Inc., the holders named therein, and BVF Partners, L.P. | 8-K | 10.3 | February 13, 2026 |
| 19.1* | Immunic, Inc. Insider Trading Policy | 10-K | 19.1 | February 22, 2024 | |
| 21.1* | List of subsidiaries of the Registrant | ||||
| 23.1* | Consent of Baker Tilly U.S. LLP, Independent Registered Public Accounting Firm. | ||||
| 24.1 | Power of Attorney (included on the signature page). | ||||
| 31.1* | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1** | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2** | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 97* | Immunic, Inc. Clawback Policy. | 10-K | 97.1 | February 22, 2024 | |
| 101.INS* | XBRL Instance Document | ||||
| 101.SCH* | XBRL Taxonomy Extension Schema Document. | ||||
| 101.CAL* | XBRL Taxonomy Extension Calculation Linkbase Document. | ||||
| 101.DEF* | XBRL Taxonomy Extension Definition Linkbase Database. | ||||
| 101.LAB* | XBRL Taxonomy Extension Label Linkbase Document. | ||||
| 101.PRE* | XBRL Taxonomy Extension Presentation Linkbase Document. | ||||
| 104* | Cover Page Interactive Data File | ||||
| + | Indicates a management contract or compensatory plan or arrangement. |
|---|---|
| * | Filed herewith |
| ** | In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management’s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.